Second-line chemotherapy for non-small cell lung cancer (2002)

Peer-Reviewed Study · Bonfill X, Serra C, Sacristan M, Nogue M, Losa F, Montesinos J (Cochrane Database Syst Rev 2002;(2):CD002804) · 2002

Bonfill X et al., 2002: Cochrane review of second-line chemotherapy in relapsed advanced NSCLC; only one trial (204 patients, docetaxel versus best supportive care) met criteria. Docetaxel gave 2.4 months extra median survival (7.0 vs 4.6 months) after the dose was cut from 100 to 75 mg/m2 following toxic deaths.

Definitive recommendations cannot be made since evidence is only available from one randomised controlled trial which, though of reasonable quality had a number of limitations.

Abstract (REVIEWER'S CONCLUSIONS)

Bonfill X et al., 2002: Cochrane review of second-line chemotherapy in relapsed advanced NSCLC; only one trial (204 patients, docetaxel versus best supportive care) met criteria. Docetaxel gave 2.4 months extra median survival (7.0 vs 4.6 months) after the dose was cut from 100 to 75 mg/m2 following toxic deaths. Funder: internal – Hospital de la Santa Creu i Sant Pau and Iberoamerican Cochrane Centre; external – Instituto de Salud Carlos III (contract 10035), Spanish Ministry of Health. Conflicts: 'None known'. Drug: docetaxel (maker not named in review). Comparator: best supportive care. The review states there is 'no evidence to support second-line treatment of patients with poor performance status'. PMC6993946. Study type: review.